Griffin Securities restated their buy rating on shares of Intrexon Corporation (NYSE:XON) in a research note published on Friday, October 6th. They currently have a $55.00 price target on the biotechnology company’s stock.
Other equities analysts also recently issued reports about the company. BidaskClub downgraded Intrexon Corporation from a hold rating to a sell rating in a research report on Friday, August 4th. Zacks Investment Research downgraded Intrexon Corporation from a hold rating to a sell rating in a research report on Thursday, July 13th. JMP Securities reaffirmed an outperform rating and set a $42.00 price target on shares of Intrexon Corporation in a research report on Thursday, October 5th. Finally, Northland Securities set a $30.00 price target on Intrexon Corporation and gave the stock a buy rating in a research report on Monday, August 7th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus price target of $43.20.
Intrexon Corporation (XON) opened at 18.24 on Friday. Intrexon Corporation has a 1-year low of $17.03 and a 1-year high of $32.90. The firm’s market capitalization is $2.20 billion. The company has a 50 day moving average price of $19.13 and a 200-day moving average price of $21.02.
Intrexon Corporation (NYSE:XON) last announced its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.05. The business had revenue of $54.40 million during the quarter, compared to analyst estimates of $57.17 million. Intrexon Corporation had a negative return on equity of 19.08% and a negative net margin of 60.63%. The company’s revenue for the quarter was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.42) earnings per share. On average, analysts forecast that Intrexon Corporation will post ($0.87) EPS for the current fiscal year.
In other news, CEO Randal J. Kirk purchased 132,625 shares of the business’s stock in a transaction dated Friday, August 11th. The stock was acquired at an average price of $18.85 per share, for a total transaction of $2,499,981.25. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Andrew J. Last purchased 2,000 shares of the business’s stock in a transaction dated Monday, August 14th. The shares were purchased at an average price of $19.99 per share, with a total value of $39,980.00. Following the acquisition, the chief operating officer now directly owns 2,000 shares in the company, valued at $39,980. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 144,569 shares of company stock valued at $2,719,429. 55.10% of the stock is owned by insiders.
Several institutional investors have recently added to or reduced their stakes in XON. State Street Corp lifted its position in shares of Intrexon Corporation by 34.0% during the 1st quarter. State Street Corp now owns 2,707,242 shares of the biotechnology company’s stock worth $53,664,000 after purchasing an additional 687,406 shares during the last quarter. First Trust Advisors LP lifted its position in Intrexon Corporation by 32.5% in the second quarter. First Trust Advisors LP now owns 1,537,088 shares of the biotechnology company’s stock valued at $37,028,000 after acquiring an additional 376,780 shares during the last quarter. Vanguard Group Inc. lifted its position in Intrexon Corporation by 5.6% in the first quarter. Vanguard Group Inc. now owns 4,286,362 shares of the biotechnology company’s stock valued at $84,954,000 after acquiring an additional 226,090 shares during the last quarter. Credit Suisse AG lifted its position in Intrexon Corporation by 273.7% in the first quarter. Credit Suisse AG now owns 183,555 shares of the biotechnology company’s stock valued at $3,638,000 after acquiring an additional 134,434 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in Intrexon Corporation by 60.0% in the first quarter. Goldman Sachs Group Inc. now owns 144,428 shares of the biotechnology company’s stock valued at $2,862,000 after acquiring an additional 54,179 shares during the last quarter. 82.11% of the stock is owned by institutional investors and hedge funds.
Intrexon Corporation Company Profile
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with our FREE daily email newsletter.